瞄准生命健康产业

Group 1 - The "Chanrong Zhejiang Medicine Zhongying Fuyiao (Hangzhou) Equity Fund" has been officially registered with a first phase scale of 500 million yuan, marking it as the first pharmaceutical-themed AIC pilot fund in Hangzhou and the first successful registration of an AIC pilot fund in 2026 [2][3] - The AIC pilot fund aims to optimize the asset-liability structure of enterprises and promote industrial upgrades through market-oriented and legal methods, including debt-to-equity swaps and strategic equity investments [2] - The fund is established with the support of various governmental departments and aims to effectively connect policy resources with financial capital [2] Group 2 - The fund will focus on investing in high-growth technology innovation enterprises in the life and health industry, particularly in biopharmaceuticals, high-end medical devices, and medical consumables within Hangzhou and across Zhejiang province [3] - The Bank of China will leverage its global network and comprehensive service advantages to provide value-added services such as cross-border technology cooperation and listing guidance for invested enterprises [3] - The fund has already identified multiple high-growth projects covering innovative drugs and medical devices, with a strategic focus on empowering technology companies and emerging industries in Hangzhou [3]